Brought to you by 
Sanofi-Aventis spins off Novexel
Dec 2004
Executive Summary
Sanofi-Aventis has spun off a new anti-infectives company it will call Novexel, which has received €40mm ($53mm) in venture funding. The investors, which hold a 66% interest in the company, were led by Atlas Venture and included Sofinnova Partners, 3i, and Novo AS. Sanofi-Aventis retains a 22% stake.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
- Spin-Off
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi-Aventis spins off Novexel
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice